Literature DB >> 12112774

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Julia Emerson1, Margaret Rosenfeld, Sharon McNamara, Bonnie Ramsey, Ronald L Gibson.   

Abstract

We conducted a registry-based study to determine prognostic indicators of 8-year mortality and morbidity in young children with cystic fibrosis (CF). Patients ages 1-5 years from the 1990 U.S. Cystic Fibrosis Foundation (CFF) National Patient Registry served as the study cohort (N = 3,323). Registry data provided information on baseline characteristics in 1990, 8-year mortality, and clinical outcomes in 1998.P. aeruginosa respiratory infection was found to be a major predictor of morbidity and mortality. The 8-year risk of death was 2.6 times higher in patients who had respiratory cultures positive for P. aeruginosa in 1990 (95% confidence interval 1.6, 4.1) than in children without P. aeruginosa in their respiratory cultures. Culture-positive patients in 1990 also had a significantly lower percent predicted forced expiratory volume in 1 sec (FEV(1)) and weight percentile at follow-up, and they had an increased risk of continued P. aeruginosa respiratory infection and hospitalization for acute respiratory exacerbation in 1998. Among the other predictors of increased morbidity and mortality were lower baseline weight percentiles and number of CF-related hospitalizations during the baseline year.These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12112774     DOI: 10.1002/ppul.10127

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  316 in total

1.  Cystic and non-cystic fibrosis Pseudomonas aeruginosa isolates are not differentiated by the quorum-sensing signaling and biofilm production.

Authors:  Leandro Reus Rodrigues Perez; Ana Lúcia Peixoto de Freitas; Afonso Luís Barth
Journal:  Curr Microbiol       Date:  2011-11-03       Impact factor: 2.188

Review 2.  Inhaled antibiotics in cystic fibrosis: what's new?

Authors:  Simon Langton Hewer
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

3.  Quantile regression for doubly censored data.

Authors:  Shuang Ji; Limin Peng; Yu Cheng; HuiChuan Lai
Journal:  Biometrics       Date:  2011-09-27       Impact factor: 2.571

4.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

5.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.

Authors:  Michael W Konstan; Patrick A Flume; Matthias Kappler; Raphaël Chiron; Mark Higgins; Florian Brockhaus; Jie Zhang; Gerhild Angyalosi; Ellie He; David E Geller
Journal:  J Cyst Fibros       Date:  2010-11-12       Impact factor: 5.482

6.  Pseudomonas aeruginosa Inhibits the Growth of Scedosporium and Lomentospora In Vitro.

Authors:  Sharon C-A Chen; Shilpa Patel; Wieland Meyer; Belinda Chapman; Hong Yu; Karen Byth; Peter G Middleton; Helena Nevalainen; Tania C Sorrell
Journal:  Mycopathologia       Date:  2017-05-16       Impact factor: 2.574

7.  Long-term culture and cloning of primary human bronchial basal cells that maintain multipotent differentiation capacity and CFTR channel function.

Authors:  Jennifer R Peters-Hall; Melissa L Coquelin; Michael J Torres; Ryan LaRanger; Busola R Alabi; Sei Sho; Jose F Calva-Moreno; Philip J Thomas; Jerry W Shay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-05-03       Impact factor: 5.464

8.  Resource Use Evaluation of Tobramycin Formulations in a State Medicaid Program.

Authors:  Shellie L Keast
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Mar-Apr

9.  Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model.

Authors:  Laura M Filkins; Jyoti A Graber; Daniel G Olson; Emily L Dolben; Lee R Lynd; Sabin Bhuju; George A O'Toole
Journal:  J Bacteriol       Date:  2015-04-27       Impact factor: 3.490

Review 10.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.